Search Results for: Pharma: Clinical Roundup
-
Clavis Brings in $25.7M to Get AML Drug Through Phase III
BioWorld Today Contributing Writer Clavis Pharma ASA raised $25.7 million in a private placement of 4.4 million new shares, at NOK35 per share (US$5.84), a sum that will carry the firm for two years...Other activities to be funded include preclinical proof of concept and early clinical development of CP-4200 and companion diagnostic development for hENT1 (human equilibrative nucleoside transporter 1) biomarkers...Tranche 2, of 2.285 million new shares, will be subject to approval by an extraordinary -
NeuroTherapeutics Pharma Gets $43M Series B for Epilepsy, Pain
Staff Writer Despite the difficult venture capital markets, NeuroTherapeutics Pharma Inc. (NTP) raised a whopping $43 million in Series B financing to advance its epilepsy and pain compounds into clinical trials -
NuPathe Files for $86M IPO Ahead of Migraine Patch NDA
Leerink Swann, Lazard Capital Markets LLC, Thomas Weisel Partners and Needham & Co...DARA has two clinical-stage candidates: KRN5500, which is in Phase II for neuropathic pain in cancer patients, and DB959, a dual PPAR delta/gamma agonist in Phase I development for Type II diabetes -
With PDUFA Date Approaching, Cell Therapeutics Raises $20M
NovaDel Pharma Inc., of Bridgewater, N.J., entered a purchase agreement to raise approximately $1.5 million through the sale of 9 million shares of its common stock to institutional investors at a price of $0.165 per share...Chardan Capital Markets LLC served as the placement agent -
With an Eye Toward an NDA, Optimer Seeks $47M Offering
Emisphere Technologies Inc., of Cedar Knolls, N.J., said that Novartis Pharma AG, of Basel, Switzerland, has agreed to further extend the maturity date of Emisphere's convertible promissory note to May 26...The company intends to use the proceeds to fund clinical and regulatory activities for picoplatin as a second-line therapy for small-cell lung cancer patients with refractory disease following first-line treatment with platinum-containing chemotherapy, and to support partnering efforts to -
Adocia Raises $20M to Boost Protein Chaperone Technology
We have established collaborations with two big pharma companies on that," Soula said...Wharton Capital Markets LLC acted as exclusive placement agent -
Past Elesclomol Setback, Synta Raises $25M in Public Offering
Funds will go toward R&D, clinical work, manufacturing, working capital and general corporate purposes...The company agreed to put elesclomol on clinical hold, which meant also suspending earlier studies including a Phase I/II trial in prostate cancer, and London-based GSK terminated its collaboration shortly thereafter. (See BioWorld Today, March 2, 2009.) Though Synta still has hopes of restarting the elesclomol program - though possibly in some other indication besides melanoma, since -
Ironwood Spruces for IPO Bid; Joins Parade with $172M Filing
Proceeds will fund a Phase III combination Reolysin and paclitaxel/carboplatin trial with platinum-failed head and neck cancers, as well as other clinical and R&D activities and general corporate purposes...The company expects to use the net proceeds of about $7.3 million to focus on regulatory and partnering activities for picoplatin, clinical development, other general corporate purposes and working capital...Those funds will be used for business development activities and other general corporate -
Does Rush of New Money Mean EU Financial Tide Has Turned?
We need additional activity on the capital markets to enable biotechnology companies to make progress with their clinical programs...Sinapis Pharma Inc., of Jacksonville, Fla., completed a Series A preferred stock offering that raised $510,000 for its ongoing drug development program -
Financings Roundup
LLC, and RBC Capital Markets acted as co-managers...AspenBio Pharma Inc., of Castle Rock, Colo., closed its public offering of 5.155 million shares of common stock at $1.70 per share...Cardiome Pharma Corp., of Vancouver, British Columbia, said more than $27.5 million of common shares were validly tendered by the deadline of its Dutch auction tender offer -
Allos Expands Offering, Adds $100M for Folotyn Launch Prep
LLC and RBC Capital Markets, exercise their full overallotment option of 2.1 million shares...AspenBio Pharma Inc., of Castle Rock, Colo., priced a public offering of 4.5 million shares of common stock at $1.70 each -
Vivus Raising $95M in Stock Sale Ahead of Expected Partner Talks
That tells us big pharma companies were thinking about obesity," Yoo said...JMP Securities LLC, Lazard Capital Markets LLC and Merriman Curhan Ford are acting as co-managers of the offering...The company's clinical trial programs with lead product JX-594 will now be funded through 2010 -
Shopping Spree Due for Onyx? $310M Opens 'Any-Stage' Door
and Lazard Capital Markets LLC serving as co-managers...In May, the company filed suit against its big pharma partner, accusing Bayer of developing a slightly different version of Nexavar on its own that could compete against the jointly owned product. (See BioWorld Today, May 19, 2009.) Onyx, which reported net income of $15 million, or 27 cents per share, for the second quarter, expects to have about 61 million shares outstanding following the public offering -
ImmunoGen Pads Cash Balance with $25M Direct Stock Offering
Assistant Managing Editor With several internal and partnered programs in or about to begin clinical development, cancer drug development firm ImmunoGen Inc...The company reported very early data earlier this month at the American Society of Clinical Oncology meeting in Chicago, showing that one of six patients treated had a notable response to treatment...Clinical findings from those studies are anticipated in the fourth quarter -
Orexigen Prices $77M Follow-On as Obesity Trials Move Ahead
But many other biotech and big pharma options are in development, including Vivus Inc.'s Qnexa (phentermine and topiramate) and Arena Pharmaceuticals Inc.'s lorcaserin hydrochloride, just to name a few...served as book-running manager, with Lazard Capital Markets LLC, Oppenheimer & Co -
Anesiva Boosting R&D Work With $45M Public Offering
In its prospectus, Anesiva said funds would support development work, such as clinical trials, and the company might also earmark a portion of the proceeds for acquisition of, or investment in complementary products or businesses...In other financings news: Ascendis Pharma A/S, of Copenhagen, Denmark, raised €17.6 million (US$25.7 million) in a Series A round led by Sofinnova Partners, of Paris, and co-led by Gilde Healthcare Partners, of the Netherlands, with participation by Zweite TechnoStart -
Aegerion Again Seeking IPO, Filing To Raise $86M
Remaining funds will support clinical trials of AEGR-733 and AEGR-427 (implitapide), both of which are small-molecule microsomal triglyceride transfer protein (MTP) inhibitors for hyperlipidemia, as well as preclinical studies and general corporate purposes...In June, the agency instituted a partial clinical hold on MTP inhibitor trials longer than six months, although Aegerion noted that none of its planned Phase II trials will exceed six months and it has obtained a waiver for its planned Phase -
HCV Bids In Front, Genelabs' Stock Sale Garnering $23.7M
Leerink Swann, A.G. Edwards & Sons, Inc., Merriman Curhan Ford & Co., RBC Capital Markets Inc, and Noble Financial Group served as financial advisors. -
Series D Adds $20M To Propel Koronis' Viral Extinction Drug
If clinical trials demonstrate that, too, the commercial implications could be very significant...We'll also take a look at the capital market alternatives as well...Bioxel Pharma Inc., of Ste-Foy, Quebec, entered an engagement letter with Paradigm Capital Inc -
Biodel Makes Strong Debut On Nasdaq Following $75M IPO
Net proceeds of about $39.3 million are expected to support clinical research and development programs, the commercialization and manufacturing of its product candidates, and for other general corporate purposes...acted as lead placement agent and Lazard Capital Markets LLC as co-lead agent on the offering, with Rodman & Renshaw LLC and ThinkEquity Partners LLC acting as co-placement agents. (See BioWorld Today, May 8, 2007